The same day Bristol-Myers Squibb shook up its board to satisfy one activist investor, the drugmaker was faced with ­another: Carl Icahn, whose interest is fuelling speculation the company could soon be put on the auction block. The …
Bristol-Myers’ rheumatoid arthritis treatment Orencia ... company as it faces a plethora of patent losses over the next few years,” Morningstar senior stock analyst Damien Conover wrote in a note to clients on Jan. 28. The first phase of work …
Bristol-Myers Squibb said Wednesday it had completed its tender offer ... has operations in Wilmington and Newark, Del. The stock purchase price for Amylin was $31 per share.
Nov 10 (Reuters) - Bristol-myers Squibb Co ::U.S. Food and Drug Administration expands approval of Sprycel (dasatinib) to include treatment of children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic …
DENVER BUSINESS JOURNAL - Array BioPharma and pharmaceutical giant Bristol-Myers Squibb will test the effectiveness of Array’s drug binimetinib in combination with a Bristol-Myers’ immunotherapy drug as a treatment for …
9News6mon
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that, per the licensing agreement for lirilumab, Bristol-Myers Squibb has paid Innate Pharma a US$15 million milestone payment for the …
Biotech major Biocon has signed an option agreement with Bristol-Myers Squibb Company for Biocon‘s IN-105, a prandial oral insulin product candidate. Biotech major Biocon has signed an option agreement with Bristol-Myers Squibb …
Currently, the 14-day ADX for Bristol-Myers Squibb Company (BMY) is sitting at 19.26. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company's stock. …